



9th September 2016

BG's Wake Up Call

	Last close	Daily chg (%)	Chg YTD (%)
Indices			
Dow Jones	18479.91	-0.25%	+6.05%
S&P 500	2181.3	-0.22%	+6.72%
Nasdaq	5259.48	-0.46%	+5.03%
Nikkei	16965.76	+0.04%	-10.90%
Stoxx 600	349.324	-0.32%	-4.51%
CAC 40	4542.2	-0.34%	-2.05%
Oil /Gold			
Crude WTI	47.62	+4.66%	+28.01%
Gold (once)	1344.34	-0.04%	+26.54%
Currencies/Rates			
EUR/USD	1.12745	+0.28%	+3.79%
EUR/CHF	1.09275	+0.30%	+0.49%
German 10 years	-0.129	-30.97%	-120.30%
French 10 years	0.15	+49.62%	-84.73%

Economic releases :

Date	
9th-Sept	CNY - CPI Aug (1.3%A , 1.7%E) FR - Industrial Production Jul. DE - Trade Balance GB - Trade Balance US - Wholesale inventories US - Baker Hughes Rig Count

Upcoming BG events :

Date	
13th-Sept	Thematic Breakfast with ARCEP
14th-Sept	SAINT GOBAIN (BG Luxembourg roadshow)
22nd-Sept	Thematic Lunch with HC specialist
30th-Sept	Thematic Breakfast with Vimpelcom
28th-Oct	IMERYS (Paris roadshow)
14th-Nov/ 15th-Nov	4th Paris Healthcare Conference

Recent reports :

Date	
7th-Sept	FRESENIUS : ¡Salud!
6th-Sept	WIRECARD Ready to reconnect with the fundamentals
24th-Aug	AMS Catching the ball when it bounces - all a question of timing
26th-Jul	NICOX Don't turn a blind eye to opportunities
21st-Jul	SEMICONDUCTORS : Looking for lost growth
13th-Jul	Oncology is an increased focus

List of our Reco & Fair Value : Please click here to download



ALTRAN TECHNOLOGIES

BUY, Fair Value EUR15 vs. EUR14 (+11%)

H1 2016 analysts' meeting feedback: comfortable with steady margin improvement

We reiterate our Buy rating and raise our DCF-derived fair value to EUR15 from EUR14 on fine-tuned medium-term WCR assumptions as a percentage of sales (0% vs. 1%). Although the turnaround in Germany requires a lot of attention due to short-term headwinds (transition to work packages from AÜG, fixing the Stuttgart branch) which have delayed it by one quarter, we consider Altran is firmly engaged in a linear operating margin improvement year after year until 2020.

ENGIE

BUY, Fair Value EUR16,5 vs. EUR16,8 (+12%)

The twelve labours of Engie (full report published today)

Following the H1-16 results and June's Investor Workshop, we have reviewed our model notably to reflect Engie's brand new business organisation. We have identified twelve tasks and challenges that have been faced or have to be faced by the company in the years to come. Completing these challenges will lead to a very different company by 2018 and should imply a potential re-rating due to the company's increased focus on regulated and contracted activities. We confirm our Buy rating and slightly lower our FV to EUR16.5 (vs. EUR16.8) following adjustments we made in our model.

SEMICONDUCTORS

A strong start to Q3 with July well above historical seasonality and a positive view on August

July sales came out better than the seasonal average. According to WSTS data, unadjusted global semiconductor sales stood at USD27.7bn, down 2.1% on a sequential basis and up 4.6% on a yearly basis. This was 720bps above our 5-y historical benchmark pointing to a sequential decrease of 9.3% in July. Computer processors, DRAM and flash memory were particularly strong in July while analogue was broadly in line with seasonal figures. Overall, seven-month aggregated sales fell 4.5% yoy but continued to improve as expected (YTD sales were down 6.5% in May). We expect sales to continue to improve thanks to an easier comparison basis in H2.

In brief...

VINCI, New toll roads concession in LatAm for Vinci

CIAGEN, New US guidelines favouring use of QuantIFERON-TB

TMT

Altran Technologies

Price EUR13.56

H1 2016 analysts' meeting feedback: comfortable with steady margin improvement

Fair Value EUR15 vs. EUR14 (+11%)

BUY

Bloomberg	ALTR.FP
Reuters	ALTR.PA
12-month High / Low (EUR)	13.6 / 9.8
Market Cap (EUR)	2,383
Ev (BG Estimates) (EUR)	2,545
Avg. 6m daily volume (000)	211.5
3y EPS CAGR	16.3%

We reiterate our Buy rating and raise our DCF-derived fair value to EUR15 from EUR14 on fine-tuned medium-term WCR assumptions as a percentage of sales (0% vs. 1%). Although the turnaround in Germany requires a lot of attention due to short-term headwinds (transition to work packages from AÜG, fixing the Stuttgart branch) which have delayed it by one quarter, we consider Altran is firmly engaged in a linear operating margin improvement year after year until 2020.

ANALYSIS

- Germany is a strong focus, fighting against headwinds.** Revenue prospects remain positive, especially in automotive (+6%, strong growth despite the exit of German carmakers from the staffing model and Volkswagen slashing its R&D budget), aeronautics (+10%), life sciences (+23%), energy, and industrial/electronics (+43%), while in telecoms Altran is up 5%. Out of the 1.1ppt operating margin improvement in H1 2016, 0.6-0.7ppt stemmed from calendar tailwinds (2-3 days), and 0.3-0.4ppt stemmed from operating improvement (SG&A). As calendar effects will reverse, the H2 2016 margin is set to suffer from headwinds, but operating improvement is expected to continue. For Germany management expects flattish sales and an operating profit around breakeven in 2016 (it was slightly loss-making in H1) given the transition to work packages from AÜG and some difficulties experienced in Stuttgart. It confirmed, Germany will be back to growth in H2 - albeit benefiting from calendar tailwinds - based on client wins and a promising sales pipeline.

- Update on 'Altran 2020 Ignition' plan.** Management remains firm on its aim to increase operating margin steadily year after year until 13% for 2020. On the pillars of the 'Altran 2020 Ignition' plan, the status: 1) on augmented value, out of the five up-and-running World Class Centres, Industrial Analytics (formerly Tessella) is ahead of schedule with a 17%+ margin, the others are small (of which two need to be reworked), and three other ones are to be launched by end 2016, the industrialisation programme is delivering well, an Altran Consulting brand has been launched to provide 2,000 "top gun" experts for strategic meetings with C-level executives; 2) on offshoring, with 4,000 engineers on board, Altran sees early success in semiconductors, automotive and telecoms, the goal still being to have 10,000+ engineers or 15% of revenues by end 2020; 3) on geographic expansion, the US is now the second largest country for Altran according to future reporting standards, which are expected to be put in place next year; 4) on operational excellence, senior management changes have been implemented recently in the US, and in Germany, Scandinavia, Belgium and the Netherlands and they are expected to restore a positive sales dynamic and improve profitability for the Northern Europe region.

- Free cash flow: not an issue, but needs to be monitored.** Strong lfl revenue growth and calendar tailwinds negatively impacted free cash flow in H1 2016 as it generated a high level of account receivables (WCR up EUR104m), but DSOs fell by 6.8 days year-on-year. Management remains confident in generating strong free cash flow in H2 2016, in the same vein as last year taking into account calendar effects. Now that the restructuring in Germany is close to completion, management is no longer closed to acquisitions in the country if an opportunity arises.

VALUATION

- Altran's shares are trading at est. 11.9x 2016 and 9.8x 2017 EV/EBIT multiples.
- Net debt on 30th June 2016 was EUR217.2m (net gearing: 28%).

NEXT CATALYSTS


Q3 2016 sales on 27th October before markets open.

	1 M	3 M	6 M	31/12/15
Absolute perf.	6.5%	5.6%	25.9%	9.8%
Softw. & Comp.	4.4%	9.3%	14.7%	7.6%
DJ Stoxx 600	2.3%	1.4%	3.5%	-4.5%

YEnd Dec. (€m)	2015	2016e	2017e	2018e
Sales	1,945	2,127	2,320	2,482
% change		9.4%	9.1%	7.0%
EBITDA	208	237	277	317
EBIT	155.0	188.0	230.0	267.0
% change		21.3%	22.3%	16.1%
Net income	123.0	140.0	167.0	193.0
% change		13.8%	19.3%	15.6%

	2015	2016e	2017e	2018e
Operating margin	9.6	10.1	10.8	11.6
Net margin	5.2	5.7	6.5	7.1
ROE	12.6	13.9	15.4	16.1
ROCE	15.0	15.2	17.0	19.5
Gearing	18.0	19.0	7.0	-4.0

(€)	2015	2016e	2017e	2018e
EPS	0.70	0.80	0.95	1.10
% change	-	14.3%	18.8%	15.8%
P/E	19.4x	16.9x	14.3x	12.3x
FCF yield (%)	3.4%	4.6%	6.0%	7.0%
Dividends (€)	0.19	0.23	0.28	0.33
Div yield (%)	1.4%	1.7%	2.1%	2.4%
EV/Sales	1.3x	1.2x	1.1x	0.9x
EV/EBITDA	12.1x	10.7x	8.9x	7.4x
EV/EBIT	13.6x	11.9x	9.8x	8.1x



Analyst :
 Gregory Ramirez
 33(0) 1 56 68 75 91
 gramirez@bryangarnier.com

Sector Team :
 Richard-Maxime Beaudoux
 Thomas Coudry
 Dorian Terral

Utilities

ENGIE

Price EUR14.67

The twelve labours of Engie (full report published today)

Fair Value EUR16,5 vs. EUR16,8 (+12%)

BUY

Bloomberg	ENGI.FP
Reuters	ENGIE.PA
12-month High / Low (EUR)	16.6 / 13.1
Market Cap (EURm)	35,726
Ev (BG Estimates) (EURm)	72,890
Avg. 6m daily volume (000)	5 430
3y EPS CAGR	-17.7%

Following the H1-16 results and June's Investor Workshop, we have reviewed our model notably to reflect Engie's brand new business organisation. We have identified twelve tasks and challenges that have been faced or have to be faced by the company in the years to come. Completing these challenges will lead to a very different company by 2018 and should imply a potential rerating due to the company's increased focus on regulated and contracted activities. We confirm our Buy rating and slightly lower our FV to EUR16.5 (vs. EUR16.8) following adjustments we made in our model.

	1 M	3 M	6 M	31/12/15
Absolute perf.	0.3%	5.2%	4.7%	-10.1%
Utilities	0.2%	0.3%	5.2%	-2.8%
DJ Stoxx 600	2.7%	1.2%	2.8%	-4.2%

ANALYSIS

- We take the opportunity of this note to transfer coverage of Engie to Pierre-Antoine Chazal.
- Twelve tasks to be undertaken...** During June's Investor Workshop, Engie gave more colour to its transformation plan. We have identified **twelve tasks that have been faced or have to be faced by the company in the years to come**. Some are already well under way (enhanced brand recognition, 40% of the disposals programme already completed or about to be completed, strong visibility on the company's dividends) while other structural ones should be sped up in the months and years to come (development in renewables, reduced exposure to commodities, building of a customers' solutions franchise).
- ... to become stronger:** all in all, we believe **the successful completion** of all these tasks and Engie's transformation plan would lead to **a significantly different company by 2018 and would trigger a potential rerating** on the stock following the **company's increased focus on contracted and regulated activities** as well the expected reduced exposure to commodities.
- Buy, FV at EUR16.5:** We maintain our **Buy rating** as we remain confident of Engie's ability to deliver its transformation plan. We value Engie through a SOTP valuation which implies a **FV of EUR16.5**.
- Note that our DCF-based valuation implies a **EUR17.0** equity value per share once the transformation plan is completed (vs. **EUR13.5** without any further disposals), i.e. **two times more upside** (c. 16%) **than downside** (c. 8%).

YEnd Dec. (EURm)	2015	2016e	2017e	2018e
Sales	69,883	65,541	63,898	64,900
% change		-6.2%	-2.5%	1.6%
EBITDA	11,261	10,852	10,597	10,946
EBIT	-3,243	6,237	6,018	6,287
% change		NS	-3.5%	4.5%
Net income	4,950	3,175	3,152	3,330
% change		-35.9%	-0.7%	5.6%

	2015	2016e	2017e	2018e
Operating margin	-4.6	9.5	9.4	9.7
Net margin	7.1	3.9	4.0	4.2
ROE	10.2	5.3	5.3	5.6
ROCE	6.8	4.4	4.3	4.5
Gearing	61.5	55.1	59.3	58.8

(EUR)	2015	2016e	2017e	2018e
EPS	2.04	1.08	1.06	1.13
% change	-	-47.3%	-1.1%	6.8%
P/E	7.2x	13.6x	13.8x	12.9x
FCF yield (%)	0.7%	23.4%	9.0%	11.6%
Dividends (EUR)	1.00	1.00	0.70	0.70
Div yield (%)	6.8%	6.8%	4.8%	4.8%
EV/Sales	1.1x	1.1x	1.1x	1.1x
EV/EBITDA	6.6x	6.7x	6.9x	6.7x
EV/EBIT	NS	11.7x	12.1x	11.6x

VALUATION

- Buy, FV @ EUR16.5**
- At current share price, Engie is trading at **6.7x** 2016e EV/EBITDA

NEXT CATALYSTS

- 10th November: Q3-16 results



[Click here to download](#)

Analyst :
 Pierre-Antoine Chazal
 33(0) 1.56.68.75.06
 pachazal@bryangarnier.com

Sector Team :
 Xavier Caroen

Construction & Building Materials

VINCI

Price EUR68.74

New toll roads concession in LatAm for Vinci

Fair Value EUR72 (+5%)

BUY-Top Picks

Bloomberg	DG FP
Reuters	SGEF.PA
12-month High / Low (EUR)	69.7 / 55.8
Market Cap (EURm)	40,941
Avg. 6m daily volume (000)	1,594

	1 M	3 M	6 M	31/12/15
Absolute perf.	2.2%	3.9%	8.6%	16.2%
Cons & Mat	4.6%	5.5%	10.7%	6.1%
DJ Stoxx 600	2.3%	1.4%	3.5%	-4.5%

	2015	2016e	2017e	2018e
P/E	19.2x	17.9x	16.4x	15.6x
Div yield (%)	2.7%	3.0%	3.2%	3.4%

ANALYSIS

- Vinci consortium, in which Vinci Highways has a 50% stake alongside local players (25% stake each) Industrial Concreto and Constructora Concreto (in which Vinci also has a 20% stake), is the future holder of a 141km toll roads concession in Colombia between Bogota and Girargot.
- The project is to operate and maintain the highway for a 30-year period, as well as to build a new 65-km lane, as well as four bidirectional tunnels. The works were awarded to a JV, in which Vinci Construction Grand Projects obtained 50%.
- The total amount of the contract is respectable at around EUR1.3bn, according to Vinci.
- This is positive news for Vinci: it proves its ability to expand its concession portfolio (not only through its Airports division). Risks exist but are under control (toll roads and construction are clearly within the core-businesses of Vinci) - but of course Colombia is more exotic than France and riskier too.

VALUATION

- FV at EUR72 derived from a SOTP

NEXT CATALYSTS

- 25th October: Q3 sales at end September

[Click here to download](#)

Eric Lemarié, elemarie@bryangarnier.com

Sector View

Semiconductors

A strong start to Q3 with July well above historical seasonality and a positive view on August

	1 M	3 M	6 M	31/12/15
Semiconductors	0.6%	20.6%	24.7%	20.4%
DJ Stoxx 600	2.7%	1.2%	2.8%	-4.2%

*Stoxx Sector Indices


Companies covered

ams	NEUTRAL	CHF29
<i>Last Price</i>	CHF33	<i>Market Cap.</i> CHF2,422m
ASML	SELL	EUR81
<i>Last Price</i>	EUR96.23	<i>Market Cap.</i> EUR41,700m
DIALOG SEMICONDUCTOR	BUY	EUR37
<i>Last Price</i>	EUR32.499	<i>Market Cap.</i> EUR2,531m
INFINEON	BUY	EUR16
<i>Last Price</i>	EUR14.82	<i>Market Cap.</i> EUR16,783m
MELEXIS	SELL	EUR48
<i>Last Price</i>	EUR60.26	<i>Market Cap.</i> EUR2,435m
SOITEC	NEUTRAL	EUR0.5
<i>Last Price</i>	EUR0.8	<i>Market Cap.</i> EUR485m
STMICROELECTRONICS	NEUTRAL	EUR6.5
<i>Last Price</i>	EUR6.81	<i>Market Cap.</i> EUR6,204m
u-blox	BUY	CHF255
<i>Last Price</i>	CHF219.1	<i>Market Cap.</i> CHF1,491m

July sales came out better than the seasonal average. According to WSTS data, unadjusted global semiconductor sales stood at USD27.7bn, down 2.1% on a sequential basis and up 4.6% on a yearly basis. This was 720bps above our 5-y historical benchmark pointing to a sequential decrease of 9.3% in July. Computer processors, DRAM and flash memory were particularly strong in July while analogue was broadly in line with seasonal figures. Overall, seven-month aggregated sales fell 4.5% yoy but continued to improve as expected (YTD sales were down 6.5% in May). We expect sales to continue to improve thanks to an easier comparison basis in H2.

ANALYSIS

- **Strong July data showed an uptick in worldwide sales but this was not really a surprise.** Unadjusted global semiconductor sales bounced back and increased on a yoy basis to USD27.7bn (up 4.6%). On a sequential basis, unadjusted global sales were down 2.1% in July compared to June. This was well above our benchmark based on five-year historical data showing an historical seasonal decrease in sales of 9.3% in July compared to June. As a result, 2016 seven-month sales came out 4.5% lower than in 2015, i.e. making up 2015 data as expected. Indeed, note that based on the visibility we now have, we expect 2016 worldwide semiconductor sales to fall slightly. We continue to see a healthy environment in the Automotive and Industrial sectors so far, while the Smartphone market remains bumpy. First data on the success of the iPhone 7 will give more colour about late-2016 momentum.
- **Asia-Pacific was particularly strong in July.** Sales in Asia (about 60% of semiconductor billings, o/w ~50% in China), were up 9% yoy in July. Conversely, European and US sales fell 2 and 3% respectively while Japan was almost flat yoy.
- **August and beyond: August data could harbour positive surprises.** July sales came out better than historical seasonality but in line with our expectations. In view of current visibility, we expect August sales to be slightly above historical seasonality (i.e. a sequential increase of 1.4%, +/-300bp). We continue to expect Smartphone sales to be bumpy although the first data from Taiwan points to a continuous improvement in momentum in this market. Six-month vehicle production remains healthy, with production of light vehicles up 6.5%, of which +7% yoy in China and +10% in Europe (however, the US, which accounts for a quarter of Chinese production and a third of European production, decreased by 6%). Our mid-term view has not changed and we continue to expect better momentum in H2 2016 thanks to better comparison in Automotive and Smartphones. Nevertheless, we note that ISM data for August was not particularly encouraging with the US PMI Manufacturing index at 49.4 compared with 52.6 in July. Note that we started the year with January PMI at 48.2. Chinese data also dipped slightly in August after a rebound in July with Markit PMI Manufacturing at 50.0 compared with 50.6 in July (48.4 in January) while the German Industrial production (IFO) data are also unresponsive in August (down 2.0% yoy). Overall, the semiconductor environment appears to be temporarily better than the overall industrial backdrop for August.



VALUATION

- **The 2016e P/E valuation improved significantly in August.** Our semiconductor valuation table shows that the overall valuation between the six sub-sectors of the industry continued to improve slightly in August. On average, IP & EDA vendors, and Fabless maintained the highest valuation metrics (driven by ARM acquisition) with average 2016e P/E ratios of 24.7x and 23.0x respectively (from 20.3x and 19.8x a month ago). Conversely, Foundry makers have the lowest valuation with an average 2016e P/E ratios of 13.1x (up from 11.9x a month ago). IDMs average P/E ratios also increased to 17.3x respectively (vs. 15.5x a month ago).

(to be continued next page)

BG semiconductor sub-sector valuation table

Subsector (# of comp.)	YTD stocks perf.		2016e			
	Avg. / Median	High / Low	EV/Sales	EV/EBITDA	EV/EBIT	P/E
Fabless (14)	21.9% / 14.6%	89.7% / -26.1%	2.7x	10.9x	14.8x	23.0x
Logic & Analog IDM (17)	14.8% / 11.1%	58.3% / -14.3%	3.3x	9.6x	12.7x	17.3x
Memory IDM (4)	25.3% / 24.7%	33.8% / 17.9%	0.9x	3.8x	6.4x	16.2x
Foundry (5)	13.3% / 10.1%	28.1% / -3.7%	1.6x	4.3x	13.3x	13.1x
Semi Equipmt & Materials (11)	14.1% / 6.9%	60.8% / -5.5%	2.2x	8.9x	10.0x	15.9x
Intellectual Property & EDA (10)	42.4% / 41.5%	77.5% / 12.6%	5.7x	17.0x	22.1x	24.7x


Numbers between brackets represent the number of companies in each category; green/red numbers are higher/lower data per ratio.

Sources: Thomson Reuters I.B.E.S.; Bryan Garnier & Co.

NEXT CATALYSTS

- August 2016 WSTS global billing reports, expected for early October.

August data could surprise positively



Sources: WSTS; Bryan Garnier & Co.

[Click here to download](#)



Analyst :
Dorian Terral
33(0) 1.56.68.75.92
dterral@bryangarnier.com

Sector Team :
Richard-Maxime Beaudoux
Thomas Coudry
Gregory Ramirez

Healthcare

QIAGEN

Price EUR23.80

New US guidelines favouring use of QuantiFERON-TB

Fair Value EUR26 (+9%)

BUY

Bloomberg	QIA GR
Reuters	QGEN.DE
12-month High / Low (EUR)	25.3 / 17.8
Market Cap (EURm)	5,705
Avg. 6m daily volume (000)	399.1

ANALYSIS

- Newly issued US Preventive Services Task Force (USPSTF) guidelines recommend the screening of Latent-TB in population groups qualified as high-risk by primary care physicians. These guidelines published in the JAMA replace the ones issued 20 years ago that recommended the screening of latent TB to be done by public agencies or specialists.
- Complemented by a grade B recommendation, these guidelines are expected to broaden the use of TB testing in the US. While no specific mention is made on the benefit of the QuantiFERON-TB test over the TST test, we would remind that QuantiFERON-TB test' advantages should not be overlooked: 1/ a higher specificity (99.2% vs 65.9% for the TST test), 2/ less doctor's visits (1 vs. 2 for the TST test) and hence a significantly reduced time to result (couple of hours vs. four to five days for the TST test).
- QuantiFERON-TB should represents 12% of QIAGEN's sales in 2016 (BGe USD156m), growing at over 20% in our estimates. We believe that these new guidelines, alongside with the launch of a 4th generation of tests in the US should boost sales in the region where QuantiFERON grew above 25% in H1.

VALUATION

- We reiterate our BUY rating on QIAGEN

NEXT CATALYSTS

- H2 2016: roll-out of novel products in the LS division
- Nov. 15th: IR Day in NYC

[Click here to download](#)[Hugo Solvet, hsolvat@bryangarnier.com](mailto:Hugo.Solvat@bryangarnier.com)

BG's Wake Up Call

Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

Stock rating

BUY	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
NEUTRAL	Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
SELL	Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

Distribution of stock ratings

BUY ratings 55.3%

NEUTRAL ratings 33.3%

SELL ratings 11.3%

Bryan Garnier Research Team

Healthcare Team	Pharmaceuticals	Eric Le Berrigaud <i>(Head of Equities)</i>	33 (0) 1 56 68 75 33	eleberrigaud@bryangarnier.com
	Biotech/Medtech	Mickael Chane-Du	33 (0) 1 70 36 57 45	mchanedu@bryangarnier.com
	Medtech/Biotech	Hugo Solvet	33 (0) 1 56 68 75 57	hsolvet@bryangarnier.com
Consumer Team	Luxury/Consumer Goods	Loïc Morvan	33 (0) 1 70 36 57 24	lmorvan@bryangarnier.com
	Beverages	Nikolaas Faes	33 (0) 1 56 68 75 72	nfaes@bryangarnier.com
	Retailing	Antoine Parison	33 (0) 1 70 36 57 03	aparison@bryangarnier.com
	Luxury /Consumer Goods	Cedric Rossi	33 (0) 1 70 36 57 25	crossi@bryangarnier.com
	Food & Beverages	Virginie Roumage	33 (0) 1 56 68 75 22	vroumage@bryangarnier.com
TMT	Video Games / Payments	Richard-Maxime Beaudoux	33 (0) 1 56 68 75 61	rmbeaudoux@bryangarnier.com
	Telecom	Thomas Coudry	33(0) 1 70 36 57 04	tcoudry@bryangarnier.com
	Software & IT Services	Gregory Ramirez	33 (0) 1 56 68 75 91	gramirez@bryangarnier.com
	Semiconductor	Dorian Terral	33 (0) 1 56 68 75 92	dterral@bryangarnier.com
Utilities	Xavier Caroen		33 (0) 1 56 68 75 18	xcaroen@bryangarnier.com
	Pierre-Antoine Chazal		33 (0) 1 56 68 75 06	pachazal@bryangarnier.com
Insurance	Olivier Pauchaut <i>(Head of Research)</i>		33 (0) 1 56 68 75 49	opauchaut@bryangarnier.com
Hotels/Business Services	Bruno de La Rochebrochard		33 (0) 1 56 68 75 88	bdelarochebrochard@bryangarnier.com
Construction/ Infrastructures Building Materials	Eric Lemarié		33 (0) 1 70 36 57 17	elemarie@bryangarnier.com
Marketing	Sophie Braincourt		33(0) 1 56 68 75 36	sbraincourt@bryangarnier.com
Market Data & Information Systems Manager	Eric Monnier		33(0) 1 56 68 75 63	emonnier@bryangarnier.com

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at www.bryangarnier.com

London	Paris	New York	Munich	New Delhi
Beaufort House 15 St. Botolph Street London EC3A 7BB Tel: +44 (0) 207 332 2500 Fax: +44 (0) 207 332 2559	26 Avenue des Champs Elysées 75008 Paris Tel: +33 (0) 1 56 68 75 00 Fax: +33 (0) 1 56 68 75 01	750 Lexington Avenue New York, NY 10022 Tel: +1 (0) 212 337 7000 Fax: +1 (0) 212 337 7002 FINRA and SIPC member	Widenmayerstrasse 29 80538 Munich Germany +49 89 2422 62 11	The Imperial Hotel Janpath New Delhi 110 001 Tel +91 11 4132 6062 +91 98 1111 5119 Fax +91 11 2621 9062
Authorised and regulated by the Financial Conduct Authority (FCA) and Financial Conduct Authority (FCA) the Autorité de Contrôle prudentiel et de résolution (ACPR)	Regulated by the			Geneva rue de Grenus 7 CP 2113 Geneve 1, CH 1211 Tel +4122 731 3263 Fax+4122731 3243 Regulated by the FINMA



BRYAN, GARNIER & Co

Disclaimer:

Bryan Garnier & Co Limited, registered in England Number 03034095 with registered office : Beaufort House 15 St Botolph Street, London EC3A 7BB , United Kingdom and its MIFID branch registered in France Number 452 605 512 with registered office : 26, Avenue des Champs Elysées 75008 Paris , France. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firms' prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Important information - This report may contain "Independent" and "Corporate/Non-independent" research reports.

Unless stated otherwise, documents in this report are classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

Independent investment research reports:

Independent investment research reports are prepared by Bryan Garnier & Co Limited and are distributed only to clients of Bryan Garnier & Co Limited (the "Firm"). Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority ("FCA") and is a member of the London Stock Exchange.

These reports are provided for information purposes only and do not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. These reports are for general circulation to clients of the Firm and as such are not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person. The information and opinions contained in these reports have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in these reports are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of these reports. Information may be available to the Firm and/or associated companies which is not reflected in these reports. The Firm or an associated company may have a consulting relationship with a company which is the subject of these reports.

Corporate or Non-Independent investment research reports:

Non-independent research reports are prepared by Bryan Garnier & Co Limited and are being distributed only to clients of Bryan Garnier & Co Limited (the "Firm"). Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority ("FCA") and is a member of the London Stock Exchange.

These reports have been sent to you for marketing purposes only and are non-independent research within the meaning of the FCA rules. These reports are not being held out as an objective or independent explanation of the matters contained in them and should not be treated as such. These reports have not been prepared in accordance with the legal requirements designed to promote the independence of investment research. The Firm is not subject to any prohibition on dealing ahead of the dissemination of investment research. These reports usually focus on emerging European growth companies. The contents of these reports as well as the other research documents on emerging growth stocks do not contain the Firm's usual stock ratings. The intrinsic value analysis is presented to provide a framework for stock valuation and discussion, and represents an estimated value on the date of publishing, which may be subject to change without notice.

The Firm's rationale for not having ratings on the stock includes the fact that such stock may have limited market capitalisation and liquidity and while the Firm may express an opinion on the near-term movement of the stock, what action investors should take depends on many factors, including liquidity/risk tolerance, holdings timeframe and investment philosophy. Emerging companies evolve rapidly with a continuous flow of information that can significantly impact the company and in the Firm's opinion this cannot be reflected by a periodic rating. Additionally, the Firm may have an advisory relationship with the company which is the subject of these reports, including for the production of sponsored research, and may expect to receive or intend to seek compensation for investment banking services from that company in the six months following the date of these reports.

To the fullest extent permitted by law, the Firm does not accept any liability whatsoever for any direct or consequential loss arising from any use of the information contained in these reports. Information may be available to the Firm which is not reflected in these reports. They are provided for information purposes only and do not constitute an offer or solicitation to buy or sell any of the securities discussed in them. These reports are for general circulation to clients of the Firm and as such are not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited immediately and should not rely on it for any purposes whatsoever.

Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC, 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co. Ltd. believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co. Ltd. and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available....